Stay updated on ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and listed countries.
    Difference
    18%
    Check dated 2025-08-31T12:18:18.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.3%
    Check dated 2025-08-17T04:37:02.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.3%
    Check dated 2025-08-10T00:29:22.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has removed a service alert regarding planned maintenance and updated the version information. Additionally, a past date and version have been deleted.
    Difference
    5%
    Check dated 2025-08-01T18:56:31.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.8%
    Check dated 2025-07-25T13:59:56.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.3%
    Check dated 2025-07-18T10:59:44.000Z thumbnail image

Stay in the know with updates to ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ONC-392 & Pembrolizumab in Platinum Resistant Ovarian Cancer Clinical Trial page.